Peter Weinstein
Chief Executive Officer Circurna
Dr. Peter Weinstein is an accomplished biotech executive, registered patent attorney, and co-founder. Peter brings over 35 years of experience in immunology, intellectual property, and business leadership. As CEO and Board Member, he guides Circurna’s strategy, leads a robust IP pipeline, and guides multidisciplinary teams from innovation to commercialization. Previously, Peter managed global IP portfolios for major therapeutics at Baxter Healthcare and advised hundreds of biotech companies as founder of Entralta, P.L.L.C. His dual expertise ensures that Circurna’s innovations are both pioneering and well-protected, strengthening the company’s competitive position in RNA therapeutics.
Seminars
Tuesday 29th September 2026
Panel Discussion: Advancing Purification Strategies for Circular & Self-Amplifying RNA to Improve Purity, Boost Yield, & Enable Scalable, Regulatory-Ready Manufacturing
2:30 pm
Key questions include:
- Are current circRNA purification strategies fundamentally overcomplicated – and where can we simplify without compromising quality?
- How do you balance purity, yield, and scalability when designing purification processes for clinical and commercial manufacturing?
- What will define a “fit-for-purpose” purification platform for circRNA as the field moves toward first-in-human and beyond?
Tuesday 29th September 2026
Eliminating Enzyme-Dependent Purification to Enable Scalable & Commercially Viable Circular RNA Manufacturing
2:00 pm
- Exploring how enzyme-free purification strategies can overcome key manufacturing bottlenecks in circular RNA development while improving scalability, recovery, and product purity
- Discussing the commercial and CMC implications of reducing purification complexity, lowering cost-per-dose, and minimizing supply chain dependency across clinical-tocommercial manufacturing
- Sharing early regulatory, process development, and scale-up considerations from advancing circular RNA therapeutics toward first-in-human studies
